Treatment of experimental chronic pulmonary mycoplasmosis

Int J Antimicrob Agents. 2006 Sep;28(3):253-8. doi: 10.1016/j.ijantimicag.2006.04.008. Epub 2006 Aug 7.

Abstract

Mycoplasma pneumoniae infection has been associated with chronic lung disease. Treatment of chronic pulmonary mycoplasmosis has not been well investigated. BALB/c mice were intranasally inoculated once with M. pneumoniae or with sterile media (uninfected controls). Infected mice were treated with telithromycin or placebo daily for 10 days in the chronic phase of disease (18 months after inoculation). Mice (n=43) were evaluated before therapy and 1 day after completion of telithromycin. Treatment of infected mice with telithromycin at 18 months after infection significantly reduced chronic pulmonary histological inflammation compared with infected mice given placebo; however, this treatment did not improve airway obstruction or airway hyperresponsiveness. Therapy longer than 10 days may be necessary to improve pulmonary function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Chronic Disease
  • Disease Models, Animal
  • Female
  • Ketolides / therapeutic use*
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Mycoplasma pneumoniae / drug effects*
  • Plethysmography
  • Pneumonia, Mycoplasma / drug therapy*
  • Pneumonia, Mycoplasma / pathology
  • Pneumonia, Mycoplasma / physiopathology

Substances

  • Anti-Bacterial Agents
  • Ketolides
  • telithromycin